Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03591575
Other study ID # LA55-0417
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date November 9, 2018
Est. completion date September 29, 2020

Study information

Verified date March 2024
Source Chiesi Canada Corp
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is looking at the effects of giving early treatment of deferiprone to young children with beta thalassemia who have started receiving regular blood transfusions but have not yet reached the criteria for starting on iron chelation therapy. Half the patients in the study will receive deferiprone, and the other half will receive placebo, for up to 12 months.


Description:

This study will give deferiprone to infants and young children with thalassemia who have started receiving regular blood transfusions but whose iron load is not yet at the level where chelation treatment would normally begin. The purpose is to see if doing this will postpone the build-up of iron without causing serious side effects. Half the children in the study will be given deferiprone at a dose that is lower than what is normally prescribed, and the other half will be given placebo. All patients will receive the assigned product three times a day for up to 12 months. Tests for signs of iron overload will be done monthly, and a patient whose iron load reaches the level where chelation therapy would normally begin will be immediately taken out of the study and started on standard chelation therapy.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date September 29, 2020
Est. primary completion date September 29, 2020
Accepts healthy volunteers No
Gender All
Age group 6 Months to 9 Years
Eligibility Inclusion Criteria: 1. Male or female aged = 6 months to < 10 years 2. Confirmed diagnosis of beta-thalassemia, as determined by high performance liquid chromatography (HPLC) or DNA testing 3. Started on a red blood cell (RBC) transfusion regimen, with a minimum of 2 transfusions already completed 4. Screening level of serum ferritin (SF) greater than >200 µg/L but not more than 600 µg/L. Since SF level may be impacted by the presence of infection, it must additionally be verified that the child has had no signs of infection in the previous 7 days, including the day of screening, and that the level of C-reactive protein (CRP) is no greater than 20% higher than the normal range for the patient's age. If there are signs of infection and/or the CRP level is above this threshold, the SF level must be checked again a minimum of one week later. Exclusion Criteria: 1. Prior use of iron chelation 2. Diagnosis of hepatitis B or C, or HIV infection 3. Evidence of abnormal liver or kidney function at screening: serum alanine transaminase (ALT) level > 5 times upper limit of normal or creatinine levels >2 times upper limit of normal 4. Disorders associated with neutropenia (absolute neutrophil count < 1.5 x 10^9/L) prior to the initiation of study medication 5. A serious, unstable illness, as judged by the investigator, during the previous 3 months before screening/baseline visit including but not limited to hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease. 6. Presence of any medical condition which in the opinion of the investigator would cause participation in the study to be unwise.

Study Design


Intervention

Drug:
Deferiprone oral solution
Liquid formulation of deferiprone, with a concentration of 80 mg/mL
Placebo
Liquid solution that matches deferiprone oral solution in appearance and taste

Locations

Country Name City State
Egypt Ain Shams University Children's Hospital Cairo
Egypt Pediatric Hospital of Cairo University Cairo
Egypt The Clinical Research Center, Faculty of Medicine, Cairo University Cairo
Indonesia Cipto Mangunkusumo National Hospital Jakarta

Sponsors (1)

Lead Sponsor Collaborator
Chiesi Canada Corp

Countries where clinical trial is conducted

Egypt,  Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Percentage of Patients in Each Treatment Group Who Still Have a Serum Ferritin Level < 1000 Micrograms Per Liter (µg/L) at Month 12 Current treatment guidelines are that standard iron chelation therapy should begin after a serum ferritin level of 1000 µg/L has been reached; thus, patients who were at this level at two consecutive visits were removed from the study so that they could start on this therapy. 12 months
Secondary Percentage of Patients With Serum Ferritin Still Below the Threshold at Different Time Points The outcome measure was the percentage of patients in each group still below the serum ferritin threshold at Months 4, 8, and 12. Without adequate chelation therapy, most patients receiving red blood cell transfusions are likely to exceed this level within a few months. However, a safety feature of the study design was that patients who reached the serum ferritin threshold were withdrawn (i.e., so that they could begin standard chelation therapy). 4, 8, and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04423237 - Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
Completed NCT04614779 - Long-term Clinical Study of CN128 in Thalassemia Patients Phase 2
Withdrawn NCT03800446 - Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood N/A
Not yet recruiting NCT02833493 - Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload N/A
Completed NCT02164253 - Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients Phase 2
Completed NCT00901199 - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload Phase 2
Completed NCT00512226 - Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia N/A
Recruiting NCT00378469 - Study of the Effects of Muscular Activity on Iron Metabolism N/A
Completed NCT00117507 - Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients Phase 4
Completed NCT00138684 - Cytochrome P450 2E1 and Iron Overload Phase 2
Completed NCT03990181 - Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement N/A
Terminated NCT02274233 - Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia Phase 1
Active, not recruiting NCT01443195 - Iron Metabolism in Small Pre Term Newborns N/A
Completed NCT01546415 - Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia Phase 4
Completed NCT01572818 - Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients N/A
Not yet recruiting NCT00980421 - Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children Phase 3
Completed NCT01047098 - Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation N/A
Recruiting NCT05294471 - Fully Automated High-Throughput Quantitative MRI of the Liver
Active, not recruiting NCT00907283 - Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA) Phase 2
Completed NCT01376622 - Changes in Pituitary Iron and Volume With Deferasirox